OverviewChartProfileKey statisticsFinancialsNewsTraderScreen

ADDEX THERAP. SF 0,01/  CH0029850754  /

München
28/06/2019  00:00:00 Chg. - Volume Bid- Ask- Market Capitalization Dividend Y. P/E Ratio
1.445EUR - 0
Turnover: 0.000		 -Bid Size: - -Ask Size: - 13.02 mill.EUR - -
GlobeNewswire 31/05 Addex Therapeutics to Release Q1 2024 Financial Results and Host Conference Call on June 6, 2024
GlobeNewswire 08/05 Addex to Present at Bio€quity Europe 2024
GlobeNewswire 29/04 Addex Provides Update on ADX71149 Phase 2 Epilepsy Study
GlobeNewswire 19/04 Addex to Present at the Swiss Biotech Day 2024
GlobeNewswire 18/04 Addex Therapeutics Reports Full Year 2023 Financial Results and Provides Corporate Update
GlobeNewswire 11/04 Addex Therapeutics to Release Full-Year 2023 Financial Results and Host Conference Call on April 18,...
GlobeNewswire 03/04 Addex and Perceptive Launch Neurosterix with $63 Million to Accelerate Development of Allosteric Mod...
GlobeNewswire 14/03 Addex to Present at the Bio-Europe Spring 2024 Conference
GlobeNewswire 31/01 Addex Enters into At-The-Market ADS Offering Agreement with H.C. Wainwright & Co. LLC.
GlobeNewswire 09/01 Addex to Present at the Swiss Equities Baader Conference
GlobeNewswire 05/01 Addex to Present at Biotech Showcase™ 2024
GlobeNewswire 14/12/2023 Addex Creates Treasury Shares
GlobeNewswire 29/11/2023 Addex Reports Q3 2023 Financial Results and Provides Corporate Update
GlobeNewswire 28/11/2023 Addex Convenes Extraordinary General Meeting
GlobeNewswire 23/11/2023 Addex Therapeutics to Release Third Quarter 2023 Financial Results and Host Conference Call on Novem...
GlobeNewswire 14/11/2023 Addex ADX71149 Epilepsy Phase 2 Study Completes Recruitment of Patients
GlobeNewswire 08/11/2023 Addex Regains Nasdaq Listing Compliance
GlobeNewswire 02/11/2023 Addex Announces Participation in the Bio-Europe 2023 Conference
GlobeNewswire 20/10/2023 Addex Completes ADS Ratio Change
GlobeNewswire 06/10/2023 Addex Announces Plan to Implement ADS Ratio Change
GlobeNewswire 20/09/2023 Addex mGlu2 NAM Cognition Program Receives €4 Million Grant
GlobeNewswire 06/09/2023 Addex Announces Participation in the H.C. Wainwright 25th Annual Global Investment Conference
GlobeNewswire 05/09/2023 Addex ADX71149 Phase 2 Epilepsy Study Expected to Readout Data in Q2 2024
GlobeNewswire 04/09/2023 Addex’s Dipraglurant Development in Post-Stroke Recovery Supported by Data Published in Brain
GlobeNewswire 24/03/2022 Addex to Present at the Bio-Europe Spring 2022 and Maxim Group – 2022 Virtual Growth Conferences